Targeted therapy for non-small-cell lung cancer: past, present and future

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) treatment has evolved, recognizing histologic subtypes and molecular drivers.
• Targeted therapies are crucial for specific molecular subgroups of advanced NSCLC.
• Key targets include epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and anaplastic lymphoma kinase (ALK).

Purpose of the Study:

• To review the development of targeted therapies for advanced non-small cell lung cancer.
• To analyze the successes and limitations of targeting EGFR, VEGF, and ALK.
• To identify future challenges and opportunities in NSCLC treatment over the next five years.

Main Methods:

• Comprehensive literature review of targeted therapy advancements in NSCLC.
• Detailed analysis of clinical trial outcomes for EGFR, VEGF, and ALK inhibitors.
• Exploration of emerging therapeutic strategies including immune checkpoint inhibitors and epigenetic therapy.

Main Results:

• Significant progress has been made in developing targeted agents for specific mutations in advanced NSCLC.
• Targeting EGFR, VEGF, and ALK has shown varying degrees of success, improving patient outcomes.
• The field is moving towards personalized medicine based on molecular profiling.

Conclusions:

• Targeted therapy has transformed advanced NSCLC treatment, with ongoing research focusing on overcoming resistance.
• Future directions include immune checkpoint inhibition, epigenetic therapy, and novel driver mutation targeting.
• Continued research is essential to address challenges and maximize therapeutic potential in the next five years.